Aspergillus Fumigatus Mold IgE

If you have asthma that keeps flaring despite inhalers, persistent coughing with mucus plugs, or a chronic lung condition that just will not settle, a hidden mold allergy may be part of the picture. Aspergillus fumigatus is a mold whose spores you inhale every day from soil, compost, dust, and damp indoor spaces, and in some people the immune system mounts a powerful allergic response to it that drives airway damage.

This test measures Af-IgE (Aspergillus fumigatus-specific immunoglobulin E), the antibody your body produces when it has become sensitized to this mold. Knowing your level helps explain why your airways are inflamed, predicts your risk of severe flares, and opens the door to a specific diagnosis called ABPA (allergic bronchopulmonary aspergillosis) that is often missed for years.

What This Antibody Reveals About Your Body

Af-IgE is a type of antibody (IgE) that your immune system specifically tailors to recognize Aspergillus fumigatus proteins. When you breathe in mold spores, immune cells in your airway lining present the mold's proteins to other immune cells, which then instruct B cells to produce Af-IgE. These antibodies coat mast cells and basophils, the cells that release chemicals like histamine when triggered.

A positive Af-IgE result means your body has built immune memory against this mold. The higher your level, the more your immune system is treating the mold as a chronic threat, fueling the type of airway inflammation that produces wheezing, mucus plugging, and over time, structural lung damage.

Allergic Bronchopulmonary Aspergillosis (ABPA)

ABPA is the most important condition this test helps detect. It happens when Aspergillus colonizes the airways of someone with asthma or cystic fibrosis and triggers an outsized allergic reaction, leading to mucus plugs, bronchiectasis (permanent widening of the airways), and recurrent flares.

International guidelines recommend Af-IgE as the preferred screening test for ABPA, using a positive cutoff of 0.35 kUA/L (kilounits of antibody per liter). At this threshold, the test catches roughly 99 to 100 cases out of 100, far better than skin prick testing which catches about 88 to 94 out of 100.

Once sensitization is confirmed, ABPA diagnosis adds total IgE above 500 IU/mL, plus eosinophil counts, fungal-specific IgG, and findings on chest imaging. Higher Af-IgE levels also predict how aggressive the disease will be: in 149 ABPA patients, those with initial Af-IgE above 9.88 kUA/L had a higher risk of flares within one year.

Severe Asthma

Even without full ABPA, mold sensitization makes asthma worse. Af-IgE-positive asthmatics tend to have lower lung function, more bronchiectasis on CT scans, and more severe disease overall. In a study of 141 asthmatics, 7.6% met criteria for ABPA, and the rest with Aspergillus sensitization still had significantly worse asthma control.

In a study of 259 children with asthma, those sensitized to Aspergillus formed a distinct, more severe subtype with higher total IgE, more eosinophils, and worse lung function than children with asthma who were not sensitized. This is sometimes treated as its own asthma endotype, separate from ABPA.

COPD and Bronchiectasis

Aspergillus sensitization is also relevant in COPD (chronic obstructive pulmonary disease). In a community study of 16,071 COPD subjects in North India, 18% were sensitized to Aspergillus, and those people had lower predicted FEV1 (a measure of how much air you can blow out in one second).

In a study of 378 COPD patients, Af-IgE positivity was tied to lower lung function and more mucus plugging on CT scans. People with both bronchiectasis and COPD show high rates of ABPA, more flares, and worse lung function than those with ABPA alone.

Cystic Fibrosis and Chronic Pulmonary Aspergillosis

In cystic fibrosis, persistent isolation of Aspergillus from the airways drives sensitization. Sensitized patients show asthma-like type-2 inflammation in their sputum and worse lung function. About 40% of people with chronic pulmonary aspergillosis (excluding asthma, COPD, ABPA) are Af-IgE sensitized, and that group has more airflow obstruction, more relapses, and worse respiratory health scores.

Reference Ranges and Thresholds

These thresholds come from ImmunoCAP testing in adults with asthma, primarily from a diagnostic accuracy study of 918 people. Different labs and assay platforms can produce different numbers, so compare your results within the same lab over time. Component-resolved testing for Asp f1, f2, f3, f4, and f6 can refine interpretation when crude extract testing is unclear.

Sources: Agarwal et al. 2025 (n=918, ImmunoCAP); Qian et al. 2025 (n=149, ABPA cohort); ISHAM-ABPA 2024 guidelines.

What Component Testing Adds

Crude Aspergillus extract IgE can be falsely positive because of cross-reactivity with other molds. Testing IgE against specific recombinant components, named Asp f1 through f6, sharpens the picture. IgE to Asp f1 and Asp f2 indicates true Aspergillus sensitization. IgE to Asp f3, f4, and f6 helps separate ABPA from simple sensitization, with pooled sensitivity around 93 to 97% and specificity around 94 to 99% in meta-analysis.

Tracking Your Trend

A single Af-IgE reading tells you whether you are sensitized, but a trend tells you whether your disease is active or controlled. Get a baseline, retest in 3 to 6 months if you are starting treatment or making changes, and at least annually thereafter if you have a known airway condition.

Important caveat: Af-IgE itself does not fall sharply with successful ABPA treatment, and may even rise modestly despite clinical improvement. Total IgE is the better marker for tracking treatment response and predicting flares. Af-IgE serves as your sensitization marker; total IgE serves as your activity marker.

What To Do With An Abnormal Result

If your Af-IgE comes back positive, the next step is not panic but a structured workup. Order a total IgE level, an Aspergillus-specific IgG, a complete blood count with differential to capture your eosinophil count, and a chest CT if you have respiratory symptoms or known asthma.

If your total IgE is above 500 IU/mL alongside a positive Af-IgE, ABPA is likely and you should see a pulmonologist or allergist familiar with the condition. Standard treatment under guideline recommendations is oral prednisolone, itraconazole, or a combination, with biologics like omalizumab as an option for steroid-sparing care. If your Af-IgE is positive but total IgE and imaging are normal, you have sensitization without full ABPA, which still warrants follow-up because it predicts more severe asthma over time.

When Results Can Be Misleading

• Cross-reactivity with other molds: crude Aspergillus extract testing can be falsely positive because of shared proteins with other fungi. If your result is borderline, ask about component-resolved testing for Asp f1 and f2.
• Atopic dermatitis: people with eczema can show falsely elevated IgE to the Asp f6 component, which can mimic ABPA on molecular testing. Interpretation should account for skin disease history.
• Active treatment: Af-IgE does not fall reliably with ABPA treatment, so a stable or slightly rising number is not a sign that therapy is failing. Use total IgE and symptoms to track treatment response.
• Recent acute infection or exacerbation: total IgE and eosinophils can spike during a flare, so timing your blood draw outside of an acute illness gives a cleaner baseline.

Why This Test Matters For Prevention

For most adults, mold allergy is treated as background noise. But if you have asthma that is harder to control than it should be, recurring sinus problems with nasal polyps, unexplained bronchiectasis, or a family history of allergic lung disease, knowing your Af-IgE status is one of the highest-yield tests you can run. Catching Aspergillus-driven airway inflammation early lets you prevent the bronchiectasis and fixed airflow obstruction that develop over years of unrecognized disease.